Romania · Delayed Price · Currency is RON Antibiotice Statistics
Total Valuation
Antibiotice has a market cap or net worth of RON 1.63 billion. The enterprise value is 1.88 billion.
| Market Cap | 1.63B |
| Enterprise Value | 1.88B |
Important Dates
The last earnings date was Thursday, November 20, 2025.
| Earnings Date | Nov 20, 2025 |
| Ex-Dividend Date | Sep 25, 2025 |
Share Statistics
Antibiotice has 671.34 million shares outstanding. The number of shares has increased by 0.03% in one year.
| Current Share Class | 671.34M |
| Shares Outstanding | 671.34M |
| Shares Change (YoY) | +0.03% |
| Shares Change (QoQ) | -0.29% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | 1.08% |
| Float | 227.92M |
Valuation Ratios
The trailing PE ratio is 28.73.
| PE Ratio | 28.73 |
| Forward PE | n/a |
| PS Ratio | 2.52 |
| PB Ratio | 1.77 |
| P/TBV Ratio | 1.83 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 32.48 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 13.60, with an EV/FCF ratio of -21.20.
| EV / Earnings | 33.04 |
| EV / Sales | 2.90 |
| EV / EBITDA | 13.60 |
| EV / EBIT | 26.19 |
| EV / FCF | -21.20 |
Financial Position
The company has a current ratio of 2.22, with a Debt / Equity ratio of 0.28.
| Current Ratio | 2.22 |
| Quick Ratio | 1.23 |
| Debt / Equity | 0.28 |
| Debt / EBITDA | 1.88 |
| Debt / FCF | -2.93 |
| Interest Coverage | 15.91 |
Financial Efficiency
Return on equity (ROE) is 6.31% and return on invested capital (ROIC) is 4.11%.
| Return on Equity (ROE) | 6.31% |
| Return on Assets (ROA) | 3.40% |
| Return on Invested Capital (ROIC) | 4.11% |
| Return on Capital Employed (ROCE) | 6.32% |
| Revenue Per Employee | 478,582 |
| Profits Per Employee | 41,964 |
| Employee Count | 1,357 |
| Asset Turnover | 0.49 |
| Inventory Turnover | 1.37 |
Taxes
In the past 12 months, Antibiotice has paid 5.84 million in taxes.
| Income Tax | 5.84M |
| Effective Tax Rate | 9.31% |
Stock Price Statistics
The stock price has decreased by -26.28% in the last 52 weeks. The beta is 0.21, so Antibiotice's price volatility has been lower than the market average.
| Beta (5Y) | 0.21 |
| 52-Week Price Change | -26.28% |
| 50-Day Moving Average | 2.50 |
| 200-Day Moving Average | 2.36 |
| Relative Strength Index (RSI) | 40.10 |
| Average Volume (20 Days) | 188,347 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Antibiotice had revenue of RON 648.96 million and earned 56.90 million in profits. Earnings per share was 0.08.
| Revenue | 648.96M |
| Gross Profit | 403.34M |
| Operating Income | 71.79M |
| Pretax Income | 62.74M |
| Net Income | 56.90M |
| EBITDA | 138.26M |
| EBIT | 71.79M |
| Earnings Per Share (EPS) | 0.08 |
Balance Sheet
The company has 14.45 million in cash and 259.70 million in debt, giving a net cash position of -245.25 million or -0.37 per share.
| Cash & Cash Equivalents | 14.45M |
| Total Debt | 259.70M |
| Net Cash | -245.25M |
| Net Cash Per Share | -0.37 |
| Equity (Book Value) | 922.94M |
| Book Value Per Share | 1.37 |
| Working Capital | 323.09M |
Cash Flow
In the last 12 months, operating cash flow was 50.34 million and capital expenditures -139.03 million, giving a free cash flow of -88.70 million.
| Operating Cash Flow | 50.34M |
| Capital Expenditures | -139.03M |
| Free Cash Flow | -88.70M |
| FCF Per Share | -0.13 |
Margins
Gross margin is 62.15%, with operating and profit margins of 11.06% and 8.77%.
| Gross Margin | 62.15% |
| Operating Margin | 11.06% |
| Pretax Margin | 9.67% |
| Profit Margin | 8.77% |
| EBITDA Margin | 21.30% |
| EBIT Margin | 11.06% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 0.02, which amounts to a dividend yield of 0.84%.
| Dividend Per Share | 0.02 |
| Dividend Yield | 0.84% |
| Dividend Growth (YoY) | -75.21% |
| Years of Dividend Growth | 2 |
| Payout Ratio | 47.48% |
| Buyback Yield | -0.03% |
| Shareholder Yield | 0.82% |
| Earnings Yield | 3.48% |
| FCF Yield | -5.43% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on May 13, 2013. It was a forward split with a ratio of 1.1819213313.
| Last Split Date | May 13, 2013 |
| Split Type | Forward |
| Split Ratio | 1.1819213313 |
Scores
Antibiotice has an Altman Z-Score of 3.67 and a Piotroski F-Score of 3.
| Altman Z-Score | 3.67 |
| Piotroski F-Score | 3 |